Revance Therapeutics Inc (RVNC)

[DaveAu]

Here is their chart of catalysts.

YE19 / Early 2020 DAXI Glabellar Lines FDA Acceptance of BLA
By April 30, 2020 DAXI Glabellar Lines Decision on biosimilar with Mylan
1H20 DAXI Forehead lines Forehead lines phase 2 data
1H20 DAXI Crow's feet Lateral canthal lines (Crow's feet) phase 2 data
2H20 DAXI Glabellar Lines Potential FDA approval and subsequent commercial launch
2H20 DAXI Cervical Dystonia Phase 3 data
2H20 DAXI Adult Uper Limb Spasticity Phase 2 data
2H20 DAXI Plantar Fasciitis Phase 2 data
1Q21 DAXI Glabellar Lines Potential product launch in Glabellar Lines, if approved
2020/2021 DAXI Glabellar Lines Potential new patnership ex-US
2020 DAXI Glabellar Lines Potential developments on regulatory pathway in China